A run on shares of Genentech, Inc. has driven the company’s market price up after it announced that its drug, Herceptin, helps women who have early-stage breast cancer. SitePunch.com reports:
Trial data over a period of five years that included more than 5000 study subjects showed that the drug in combination extended the life expectancy of women who carry a specific genetic mutation that appears in about 30 percent of all breast cancer cases.
Patients that carry the mutation usually have tumors that grow faster and recur more often compared with other types of breast cancer.
The study showed these breast cancer patients treated with the drug were about 52 percent less likely to have tumors recur compared with those not given Herceptin.
Nathan Novak at 12:24 pm
